Q-omics provides the consensus-scored MFAP3 profile across patient tissues and cancer cell-line models. MFAP3 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, MFAP3 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, MFAP3 RNA expression shows 20,182 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, THCA, and THYM as cancer lineages where MFAP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MFAP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MFAP3 survival associations across molecular data types. MFAP3 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MFAP3 RNA expression–survival associations across cancer types. High MFAP3 expression shows unfavorable associations in CESC, MESO, STAD, BLCA and ACC, but favorable associations in KIRC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify CESC as the clearest survival context for MFAP3 RNA expression.
This table summarizes MFAP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MFAP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MFAP3 shows lower tumor expression in THCA and KICH and higher tumor expression in BLCA, HNSC, LIHC and KIRC. The THCA box plot shows higher MFAP3 RNA expression in normal versus tumor tissue (log2 FC = −0.714, t-test p < 0.001).
This table shows molecular features associated with MFAP3 in patient tissues and cancer cell lines. In patient samples, MFAP3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MFAP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
